Andrew Hack - May 19, 2022 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)

Role
Director
Signature
/s/ Andrew Hack
Stock symbol
MRSN
Transactions as of
May 19, 2022
Transactions value $
$746,437
Form type
4
Date filed
5/23/2022, 05:49 PM
Previous filing
May 18, 2022
Next filing
May 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRSN Common Stock Purchase $349K +100K +1.24% $3.49 8.19M May 19, 2022 See footnotes F1, F2, F3
transaction MRSN Common Stock Purchase $346K +100K +1.22% $3.46 8.29M May 20, 2022 See footnotes F1, F2, F4
transaction MRSN Common Stock Purchase $52.2K +15.6K +0.19% $3.35 8.3M May 23, 2022 See footnotes F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS II and BCIPLS, the "Bain Capital Life Sciences Entities").
F2 Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. As a result, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.375 to $3.595, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.374 to $3.505, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.345 to $3.350, inclusive.